Drug Database
DO

docetaxel (TPU 004DO / TPU004DO)

✓ Approved

Shandong Luoxin Pharma · TUBB · 小分子

什么是 docetaxel?

docetaxel 是一种小分子,由Shandong Luoxin Pharma研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名TPU 004DO, TPU004DO
公司Shandong Luoxin Pharma
药物类别小分子
分子靶点TUBB
给药途径Injectable (Others), Intravenous (IV)
状态Approved

作用机制

分子靶点

docetaxel 作用于 1 个分子靶点:

TUBBtubulin beta class I (TUBB1, CSCSC1)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

docetaxel 针对 6 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Gastric cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer stage IV✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer metastatic✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Prostate cancer✓ Approved

注册免费账户还可查看另外 1 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedIJU case reports2026-11-18

Complete Response to Pembrolizumab in a Case of Microsatellite Instability-High, Castration-Resistant Prostate Cancer With Somatic MSH2 Mutation.

Gunji Kanako K, Hoshi Seiji S, Maruya Masahiro M, Hagino Risa R et al.

Microsatellite instability-high status has been associated with response to immune checkpoint inhibitors. However, clinical data on microsatellite instability-high castration-resistant prostate cancer and temporal changes in mismatch repair status remain limited. A 77-year-old man with castration-resistant prostate cancer underwent comprehensive genomic profiling, which showed microsatellite instability-high and tumor mutational burden-high status with a somatic MSH2 (c.366+1G>C) variant. Pembrolizumab decreased prostate-specific antigen levels and achieved a radiological complete response. Serial immunohistochemistry demonstrated preserved MSH2 expression at diagnosis and loss after docetaxel treatment, establishing a temporal change in MMR protein expression during the clinical course. Serial biopsies demonstrated a temporal loss of MSH2 expression, suggesting that MMR function and MSI status may have changed during treatment. However, acquisition of MSI-H could not be established because baseline molecular MSI status was unavailable. This case highlights the potential value of re-biopsy and reassessment of current tumor biology.

PMID 43048681
阅读全文 →
PubMedCancer reports (Hoboken, N.J.)2026-11-17

Clinically Presumed Brain Metastasis as the Initial Presentation of Prostate Cancer Harboring a BRCA2 Alteration With Subsequent Transformation to Treatment-Related Neuroendocrine Prostate Cancer: A Case Report.

Wang Yanwu Y, Wu Yingjie Y, Zhu Shaokang S, Wu Zhengrong Z et al.

Treatment-related neuroendocrine prostate cancer (t-NEPC) is an aggressive, therapy-resistant phenotype for which no standard treatment has been established. Intracranial metastasis from prostate cancer is uncommon, particularly as the initial presentation. In March 2020, a 62-year-old man presented to Nanfang Hospital, Southern Medical University, Guangzhou, China, with dizziness and blurred vision. Imaging showed disseminated prostate cancer and an intracranial lesion that was clinically presumed to represent metastasis but was not biopsied. Prostate biopsy demonstrated acinar adenocarcinoma (Gleason score 5 + 4 = 9; Grade Group 5). After androgen deprivation therapy, docetaxel, and subsequent abiraterone, a February 2022 transurethral resection specimen showed large-cell neuroendocrine carcinoma, establishing t-NEPC in the prostate. Immediately before TURP, total PSA was 0.369 ng/mL and NSE was 30.3 ng/mL. Tumor-only next-generation sequencing of the resection specimen detected BRCA2 p.I605fs and TP53 p.A83fs alterations with RB1 and PTEN copy-number losses; germline status was not assessed. Etoposide/cisplatin was initiated in March 2022, and continuous olaparib began on April 14, 2022 during cycle 2. Clinical improvement and approximately 11 months of disease stability were observed, but the contribution of either treatment cannot be isolated. The disease subsequently progressed, and the patient died 39 months after the initial diagnosis. This case underscores the distinction between a clinically presumed intracranial metastasis and histologically confirmed t-NEPC. It also highlights the diagnostic value of re-biopsy at progression and the need for cautious interpretation of biomarker changes and overlapping treatments. Prospective clinicopathological and molecular data are needed to refine the diagnosis and management of t-NEPC.

PMID 43039876
阅读全文 →
PubMedCureus2026-11-17

Local Radiotherapy and Androgen Deprivation Therapy (ADT) Monotherapy for Low-Volume Metastatic Hormone-Sensitive Prostate Cancer: Real-World Outcomes in the Era of PSMA PET-CT Staging.

Lau Yuen Hang YH, Chow Chung Hang James CHJ

Background Randomized trials established the survival benefit of primary tumor radiotherapy (RT) in low-volume metastatic hormone-sensitive prostate cancer (mHSPC), typically alongside upfront docetaxel or androgen receptor pathway inhibitors (ARPI). However, in real-world practice, systemic intensification is frequently omitted due to age, comorbidities, or cost. In parallel, diagnostic imaging has shifted from conventional CT and bone scan to PSMA PET-CT. We hypothesized that patients with low metastatic burden accurately staged via highly sensitive PSMA PET-CT can achieve durable survival with prostate RT and androgen deprivation therapy (ADT) alone. Methods We retrospectively reviewed patients with newly diagnosed, PSMA PET-CT-staged, low-volume mHSPC treated at a single center between January 2019 and April 2025. All received high-dose prostate RT and continuous ADT monotherapy. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Univariate and multivariate Cox regression models were utilized to identify prognostic factors for PFS. Results Fifty patients were identified. The most common radiotherapy fractionation was 55 Gy in 20 fractions (n=45, 90%). At a median follow-up duration of 31 months, median PFS and OS were not reached. The two-year OS and PFS were 96% and 82%, respectively. On univariate analysis, favorable prognostic factors included non-T4 stage, low PSA at six months post-RT, PSA <0.2 ng/mL at six months post-RT, and low absolute PSA nadir. PSA <0.2 ng/mL at six months post-RT remained as a significant prognostic factor in multivariate analysis. The two-year PFS for patients achieving a PSA <0.2 ng/mL at six months was higher than those with PSA ≥ 0.2 ng/mL (96% vs. 61%, HR 0.07, 95% CI 0.01-0.57, p=0.013). Conclusion While upfront systemic treatment intensification remains the current standard of care for mHSPC, for patients with low-volume disease staged by PSMA PET-CT who cannot receive or tolerate upfront systemic intensification, preliminary data show pairing prostate RT with ADT monotherapy still achieves favorable PFS and OS, and is an explorable alternative that should be validated by prospective studies. A six-month post-RT PSA threshold of <0.2 ng/mL is a significant prognostic factor for PFS and could be explored for its utility in identifying candidates for continued de-escalated therapy versus those requiring timely systemic re-intensification.

PMID 43041219
阅读全文 →
PubMedTurkish journal of pharmaceutical sciences2026-11-16

The Inhibition of Biotransformation Enzymes Affects the Response of PC3 Prostate Cancer Cell Line to Docetaxel.

Dilek Kançağı Derya D, Bedir İpek İ, Telci Dilek D, Güray Nülüfer Tülün NT

Targeting drug-metabolizing enzymes in tumor cells may improve chemoprevention and chemotherapy by providing new targets for anticancer agents or combination therapies. This study investigated whether inhibition of CYP1A1, CYP3A4, and GSTP1 by α-naphthoflavone, ketoconazole, and quercetin modulates docetaxel activity in PC3 prostate cancer cells and PNT1A prostate epithelial cells. PC3 and PNT1A cells were exposed to docetaxel either alone or in combination with inhibitors of CYP1A1, CYP3A4, and GSTP1. Sub-lethal monotherapy doses were calibrated to produce approximately 70% cell viability at 24 hours and 60% at 48 hours. Cell viability was assessed by WST-1 assay, while apoptosis and necrosis were evaluated using Annexin V staining. Enzyme activities were measured by ELSA. Cellular oxidative activity was assessed by DCFDA fluorescence analysis. In PC3 cells, calibrated monotherapy doses were: 4 µM docetaxel, 1000 nM α-naphthoflavone, 56.5 µM ketoconazole, and 300 µM quercetin. Combination treatments reduced cell viability by an additional 12-25% at 24 hours and by up to 45% at 48 hours, compared with docetaxel alone. Docetaxel treatment induced time-dependent changes in enzyme activities, whereas combination treatments markedly reduced DCFDA fluorescence signals. Co-administration of docetaxel with CYP1A1, CYP3A4, and GSTP1-related pharmacological modulators may enhance cytotoxicity in prostate cancer cells. Increased cytotoxicity was accompanied by reduced DCFDA fluorescence, indicating that enhanced treatment responses were not necessarily associated with increased oxidative fluorescence signals.

PMID 43037072
阅读全文 →
PubMedOncogenesis2026-11-16

Dual downregulation of HRK and BAD promotes BCL-xL-mediated docetaxel resistance in prostate cancer.

Alcon Clara C, Manzano-Muñoz Albert A, Ruiz de Porras Vicenç V, Servian Pol P et al.

Prostate cancer is the second most common malignancy in men. For patients who present metastatic disease, androgen deprivation therapy is the standard of care. Despite significant initial responses to anti-androgenic therapy, almost all patients progress to an incurable metastatic castration-resistant prostate cancer, facing a significant therapeutic challenge. Docetaxel is a taxane that improves response rates in these patients, but its efficacy is limited due to the development of resistance, which can be mediated through anti-apoptotic adaptations. Dynamic BH3 profiling is a functional assay that can anticipate tumors' anti-apoptotic adaptation to treatment and guide the use of specific inhibitors such as BH3 mimetics or PROTACs. In this study, we elucidate that BCL-xL is the major pro-survival protein in prostate cancer cell lines after docetaxel treatment, which can be reverted using BH3 mimetics or PROTAC strategies against this protein. We also describe for the first time that the downregulation of HRK and BAD sensitizer BH3-only proteins due to docetaxel treatment leads to BCL-xL mediated resistance in prostate cancer cells. Finally, we introduce a new functional technology that detects mitochondrial permeabilization, enabling successful testing of this therapeutic combination directly in patient‑derived prostate cancer cells.

PMID 43035508
阅读全文 →
PubMedBreast cancer research and treatment2026-11-16

Fluzoparib combined with docetaxel followed by epirubicin and cyclophosphamide as neoadjuvant therapy in HRD-positive and/or gBRCA-mutated HR+/HER2- early breast cancer: a single-arm phase II study.

Wang Zhe Z, Yang Liu L, Du Pu P, Zhao Ge G et al.

HR+/HER2- breast cancer is the most prevalent molecular subtype of breast cancer, yet overall pathological complete response (pCR) rates after neoadjuvant chemotherapy remain low. BRCA mutations and homologous recombination deficiency (HRD) may sensitize tumors to PARP inhibitors through synthetic lethality. We investigated the efficacy and safety of fluzoparib combined with neoadjuvant chemotherapy in patients with HRD-positive and/or germline BRCA (gBRCA)-mutated HR+/HER2- early breast cancer. This single-center, prospective, open-label, single-arm phase II trial (NCT07162051) enrolled women aged 18-70 years with newly diagnosed HRD-positive and/or gBRCA-mutated HR+/HER2- early breast cancer. Patients received fluzoparib combined with docetaxel during cycles 1-4, followed by epirubicin plus cyclophosphamide during cycles 5-8. The primary endpoint was the proportion of patients achieving residual cancer burden (RCB) grade 0/I. Secondary endpoints included objective response rate (ORR), pathological complete response (pCR) rate, and safety. Twenty-eight patients were enrolled between March 2023 and October 2025. Four patients (14.3%; 95% CI 4.0%-32.7%) achieved RCB 0/I, two patients (7.1%; 95% CI 0.9%-23.5%) achieved total pCR (tpCR), and six patients (21.4%; 95% CI 8.3%-41.0%) achieved breast pCR (bpCR). The ORR was 82.1%. Grade 3-4 treatment-related adverse events occurred in four patients (14.3%). No treatment discontinuations, dose reductions, treatment delays, or treatment-related deaths were observed. The addition of fluzoparib to standard neoadjuvant chemotherapy did not improve RCB 0/I rates in HRD-positive and/or gBRCA-mutated HR+/HER2- early breast cancer, although the regimen was well tolerated. Future studies should focus on gBRCA-mutated or higher-risk populations and explore optimized combination strategies, including anti-angiogenic agents. REGISTRATION CENTER, TRIAL REGISTRATION NUMBER, AND REGISTRATION DATE: This is a prospective, open label, single arm phase II clinical trial. Registry: ClinicalTrials.gov; Trial registration number: NCT07162051; Registration date:2023-02-21.

PMID 43037769
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多docetaxel